The purpose of this study is to determine the relationship between attention and quality of
life and how rivastigmine and atomoxetine alter attention in non-demented persons with
Parkinson's disease (PD).
Phase:
Phase 4
Details
Lead Sponsor:
Oregon Health and Science University
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)